Limited coverage criteria – nabumetone

Last updated on March 19, 2025

Special Authority requests can now be submitted online. It's simple and quick!

Generic name		nabumetone
Strength & form		500 mg tablet

Special Authority criteria	Approval period
For the treatment of patients who have a: Diagnosis of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, gout or lupus OR Treatment failure on optimal doses of, or intolerance to all of the following: ibuprofen, naproxen, diclofenac AND Either celecoxib OR meloxicam	Indefinite

Special Authority criteria

Approval period

For the treatment of patients who have a:

Diagnosis of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, gout or lupus

Treatment failure on optimal doses of, or intolerance to all of the following: ibuprofen, naproxen, diclofenac

AND

Either celecoxib OR meloxicam

Indefinite

Practitioner exemptions

Pediatrics
Pediatric cardiology
Pediatric general surgery
Physical medicine and rehabilitation
Rheumatology

Special notes

Treatment failure on or intolerance to the specific medications listed in the above criteria is required. Treatment failure on, or intolerance to the following NSAIDs is not sufficient: ketorolac, mefenamic acid, diclofenac potassium, naproxen sodium

Special Authority request form(s)

Log in to eForms
HLTH 5328 – General Special Authority request (PDF, 656KB)

Did you find what you were looking for?

The B.C. Public Service acknowledges the territories of First Nations around B.C. and is grateful to carry out our work on these lands. We acknowledge the rights, interests, priorities, and concerns of all Indigenous Peoples - First Nations, Métis, and Inuit - respecting and acknowledging their distinct cultures, histories, rights, laws, and governments.

More topics